Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.

被引：49
|
作者：
Reardon, David A.
Sampson, John H.
Sahebjam, Solmaz
Lim, Michael
Baehring, Joachim M.
Vlahovic, Gordana
Cloughesy, Timothy Francis
Strauss, Lewis C.
Latek, Robert Raymond
Paliwal, Prashni
Harbison, Christopher T.
Voloschin, Alfredo Daniel
Omuro, Antonio Marcilio Padula
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2014
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
    Ascierto, P. A.
    Del Vecchio, M.
    Merelli, B.
    Gogas, H.
    Arance Fernandez, A. M.
    Dalle, S.
    Cowey, C. L.
    Schenker, M.
    Grob, J. J.
    Chiarion Sileni, V.
    Marquez-Rodas, I.
    Butler, M. O.
    Di Giacomo, A. M.
    Pe Benito, M.
    Soomro, R.
    Askelson, M.
    Weber, J. S.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S656 - S656
  • [32] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.
    El-Khoueiry, Anthony B.
    Yau, Thomas
    Kang, Yoon-Koo
    Kim, Tae-You
    Santoro, Armando
    Sangro, Bruno
    Melero, Ignacio
    Kudo, Masatoshi
    Hou Ming-Mo
    Matilla, Ana
    Tovoli, Francesco
    Knox, Jennifer J.
    He, Aiwu Ruth
    El-Rayes, Bassel F.
    Acosta-Rivera, Mirelis
    Lim, Ho Yeong
    Memaj, Arteid
    Sama, Ashwin Reddy
    Hsu, Chiun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [33] Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
    Lebbe, C.
    Meyer, N.
    Mortier, L.
    Marquez-Rodas, I.
    Robert, C.
    Rutkowski, P.
    Menzies, A. M.
    Eigentler, T.
    Ascierto, P. A.
    Smylie, M.
    Ajaz, M.
    Svane, I-M.
    Gonzalez, R.
    Rollin, L.
    Saci, A.
    Grigoryeva, E.
    Pigozzo, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 737 - 737
  • [34] Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).
    Weber, Jeffrey S.
    Mandala, Mario
    Del Vecchio, Michele
    Gogas, Helen
    Arance, Ana M.
    Cowey, Charles Lance
    Dalle, Stephane
    Schenker, Michael
    Chiarion-Sileni, Vanna
    Rodas, Ivan Marquez
    Grob, Jean-Jacques
    Butler, Marcus
    Middleton, Mark R.
    Maio, Michele
    Atkinson, Victoria
    Dummer, Reinhard
    de Pril, Veerle
    Qureshi, Anila H.
    Larkin, James M. G.
    Ascierto, Paolo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with uveal melanoma (UM).
    Patel, Sapna Pradyuman
    Glitza, Isabella Claudia
    Diab, Adi
    Amaria, Rodabe Navroze
    Davies, Michael A.
    Hwu, Patrick
    Tawbi, Hussein Abdul-Hassan
    Hwu, Wen-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] ASSESSMENT OF THE IMMUNOGENICITY OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) IN COMBINATION AND POTENTIAL IMPACT ON SAFETY AND EFFICACY IN PATIENTS WITH ADVANCED MELANOMA.
    Statkevich, P.
    Passey, C.
    Park, J.
    Saeger, S.
    Bello, A.
    Roy, A.
    Agrawal, S.
    Gupta, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S9 - S9
  • [37] Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
    Omuro, Antonio
    Vlahovic, Gordana
    Lim, Michael
    Sahebjam, Solmaz
    Baehring, Joachim
    Cloughesy, Timothy
    Voloschin, Alfredo
    Ramkissoon, Shakti H.
    Ligon, Keith L.
    Latek, Robert
    Zwirtes, Ricardo
    Strauss, Lewis
    Paliwal, Prashni
    Harbison, Christopher T.
    Reardon, David A.
    Sampson, John H.
    NEURO-ONCOLOGY, 2018, 20 (05) : 674 - 686
  • [38] CLINICAL RESPONSE, PROGRESSION-FREE SURVIVAL (PFS) AND SAFETY IN PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) RECEIVING NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN CHECKMATE 069 STUDY
    Hodi, F. Stephen
    Postow, Michael A.
    Chesney, Jason
    Pavlik, Anna C.
    Robert, Caroline
    Grossman, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David
    Salama, April K.
    Taylor, Matthew
    Ott, Patrick A.
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd D.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 109 - 109
  • [39] A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma
    Schwarze, J. K.
    Bertels, C.
    Awada, G.
    Tijtgat, J.
    Tuyaerts, S.
    Cras, L.
    Vaeyens, F.
    Vanbinst, A-M.
    Everaert, H.
    Michotte, A.
    Caljon, B.
    Olsen, C.
    Janssen, T.
    Van Dooren, S.
    Forsyth, R.
    Duerinck, J.
    Neyns, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1443 - S1443
  • [40] Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: CheckMate 143.
    Sahebjam, Solmaz
    Ramkissoon, Shakti
    Baehring, Joachim M.
    Mulholland, Paul James
    Grauer, Oliver M.
    Cloughesy, Timothy Francis
    Reardon, David A.
    Lim, Michael
    Zwirtes, Ricardo F.
    Latek, Robert Raymond
    Strauss, Lewis C.
    Ligon, Keith L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345